Nicotine replacement therapy - nicotine lozenge — Competitive Intelligence Brief

Nicotine replacement therapy - nicotine lozenge (Nicotine replacement therapy - nicotine lozenge) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy. Area: Addiction.

phase 3 Nicotine replacement therapy Addiction Small molecule

Target snapshot

Nicotine replacement therapy - nicotine lozenge (Nicotine replacement therapy - nicotine lozenge) — Iowa City Veterans Affairs Medical Center. Nicotine replacement therapy lozenges work by releasing nicotine into the bloodstream to help manage withdrawal symptoms and cravings.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicotine replacement therapy - nicotine lozenge TARGET	Nicotine replacement therapy - nicotine lozenge	Iowa City Veterans Affairs Medical Center	phase 3	Nicotine replacement therapy
NRT (NicoDerm CQ)	NRT (NicoDerm CQ)	University of California, San Francisco	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicotine polacrilex lozenge	Nicotine polacrilex lozenge	University of Maryland, Baltimore	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Naltrexone Tablet and Nicotine Patch	Naltrexone Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Opioid antagonist + nicotine replacement therapy combination	Mu-opioid receptor (naltrexone); nicotinic acetylcholine receptors (nicotine)
Standard Duration Combination NRT	Standard Duration Combination NRT	University of Wisconsin, Madison	marketed	Nicotine replacement therapy combination	Nicotinic acetylcholine receptors
Nicotine Mini-Lozenge for 11 Months	Nicotine Mini-Lozenge for 11 Months	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist; Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicoderm patch first, then Aveva patch	Nicoderm patch first, then Aveva patch	University of Maryland, Baltimore	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy class)

1. University of Wisconsin, Madison · 2 drugs in this class
2. Iowa City Veterans Affairs Medical Center · 1 drug in this class
3. Massachusetts General Hospital · 1 drug in this class
4. NYU Langone Health · 1 drug in this class
5. GlaxoSmithKline · 1 drug in this class
6. University of Hawaii · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Vermont · 1 drug in this class
9. Ottawa Heart Institute Research Corporation · 1 drug in this class